Senior Editor, Diagnostic Imaging
Study: 'All Men with PSAs Between 3 and 20 ng/mL Should Undergo MRI Before Biopsy'
September 7th 2023In a study of over 23,000 men who had PSA testing, researchers found that the adoption of pre-biopsy MRI resulted in a 21 percent decrease in negative biopsies and a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 prostate cancers.
Emerging PSMA PET Agent May Offer Improved Detection of Prostate Cancer
September 7th 2023The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Can AI Match Radiologist Assessment of Screening Mammography Exams?
September 5th 2023In separate test sets that included challenging mammography cases, researchers found that artificial intelligence (AI) demonstrated similar sensitivity and specificity for detecting breast cancer in comparison to assessments from over 500 clinicians.
Study: 66 Percent of Men with Positive MRI for Prostate Cancer Had Normal PSA Levels
August 23rd 2023Two-thirds of men with a positive screening MRI for prostate cancer had PSA levels below 3 ng/mL and 91 percent of these men had clinically significant prostate cancer, according to newly published research.
New Research Shows Consequences of Delayed Diagnosis in Mammography Screening
August 22nd 2023Primary diagnostic delays in mammography screening led to a greater than 10 percent higher incidence of lymph node metastasis with invasive breast cancer in comparison to women without a primary diagnostic delay, according to new research out of the Netherlands.
Emerging Innovations in Molecular Imaging
August 21st 2023In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.
Is Pre-Imaging Biopsy Necessary for Prostate Cancer Staging in Elderly Patients?
August 17th 2023For patients 80 years of age or older that have a PSA level at 20 ng/mL or higher, PSMA PET/CT has a high likelihood of success in diagnosing and staging prostate cancer regardless of pre-imaging biopsy use, according to newly published research.
Study Reveals Tradeoffs Between Contrast-Enhanced Mammography and MRI for Supplemental Screening
August 16th 2023In a new study comparing standard breast MRI, abbreviated breast MRI and contrast-enhanced mammography in supplemental breast cancer screening, researchers found that MRI offered a greater than 14 percent higher cancer detection rate and a nearly 39 percent higher sensitivity rate than CEM.
Viz.ai Gets FDA Nod for Hypertrophic Cardiomyopathy Module
August 16th 2023The De Novo approval for Viz HCM, which assesses electrocardiograms with artificial intelligence (AI) to identify possible cases of hypertrophic cardiomyopathy (HCM), is the 12th FDA clearance of algorithms on the Viz.ai Platform.
Study: Abbreviated Non-Contrast MRI May Facilitate Early Detection of Prostate Cancer
August 11th 2023The use of non-contrast, biparametric MRI (bpMRI) for prostate cancer screening regardless of PSA values detected more clinically significant cases of prostate cancer than reserving bpMRI for patients with elevated PSA levels, according to preliminary findings from an ongoing prospective, randomized study.
CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
August 10th 2023Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence
August 8th 2023In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.
CMS Suspends IDR Process of No Surprises Act After Federal Court Vacates IDR Fee Increase
August 7th 2023The controversial Independent Dispute Resolution (IDR) process of the No Surprises Act was temporarily suspended by the CMS on August 4 due to a federal court ruling that vacated a substantial administrative fee increase and batching rule from the CMS that reportedly curtailed challenges of claim reimbursement by radiologists and other providers.